Mesenchymal stem cell therapy in type 2 diabetes mellitus
Abstract Type 2 diabetes mellitus (T2DM), which is characterized by the combination of relative insulin deficiency and insulin resistance, cannot be reversed with existing therapeutic strategies. Transplantation of insulin-producing cells (IPCs) was once thought to be the most promising strategy for...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-05-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13098-017-0233-1 |
| _version_ | 1818582682855014400 |
|---|---|
| author | Li Zang Haojie Hao Jiejie Liu Yijun Li Weidong Han Yiming Mu |
| author_facet | Li Zang Haojie Hao Jiejie Liu Yijun Li Weidong Han Yiming Mu |
| author_sort | Li Zang |
| collection | DOAJ |
| description | Abstract Type 2 diabetes mellitus (T2DM), which is characterized by the combination of relative insulin deficiency and insulin resistance, cannot be reversed with existing therapeutic strategies. Transplantation of insulin-producing cells (IPCs) was once thought to be the most promising strategy for treating diabetes, but the pace from the laboratory to clinical application has been obstructed due to its drawbacks. Mesenchymal stem cells (MSCs) harbor differentiation potential, immunosuppressive properties, and anti-inflammatory effects, and they are considered an ideal candidate cell type for treatment of DM. MSC-related research has demonstrated exciting therapeutic effects in glycemic control both in vivo and in vitro, and these results now have been translated into clinical practice. However, some critical potential problems have emerged from current clinical trials. Multi-center, large-scale, double-blind, and placebo-controlled studies with strict supervision are required before MSC transplantation can become a routine therapeutic approach for T2DM. We briefly review the molecular mechanism of MSC treatment for T2DM as well as the merits and drawbacks identified in current clinical trials. |
| first_indexed | 2024-12-16T07:53:16Z |
| format | Article |
| id | doaj.art-d8045826136545649d7ed2931c1f0079 |
| institution | Directory Open Access Journal |
| issn | 1758-5996 |
| language | English |
| last_indexed | 2024-12-16T07:53:16Z |
| publishDate | 2017-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj.art-d8045826136545649d7ed2931c1f00792022-12-21T22:38:48ZengBMCDiabetology & Metabolic Syndrome1758-59962017-05-019111110.1186/s13098-017-0233-1Mesenchymal stem cell therapy in type 2 diabetes mellitusLi Zang0Haojie Hao1Jiejie Liu2Yijun Li3Weidong Han4Yiming Mu5Department of Endocrinology, Chinese PLA General HospitalDepartment of Molecular Biology, Institute of Basic Medicine, College of Life Science, Chinese PLA General HospitalDepartment of Molecular Biology, Institute of Basic Medicine, College of Life Science, Chinese PLA General HospitalDepartment of Endocrinology, Chinese PLA General HospitalDepartment of Molecular Biology, Institute of Basic Medicine, College of Life Science, Chinese PLA General HospitalDepartment of Endocrinology, Chinese PLA General HospitalAbstract Type 2 diabetes mellitus (T2DM), which is characterized by the combination of relative insulin deficiency and insulin resistance, cannot be reversed with existing therapeutic strategies. Transplantation of insulin-producing cells (IPCs) was once thought to be the most promising strategy for treating diabetes, but the pace from the laboratory to clinical application has been obstructed due to its drawbacks. Mesenchymal stem cells (MSCs) harbor differentiation potential, immunosuppressive properties, and anti-inflammatory effects, and they are considered an ideal candidate cell type for treatment of DM. MSC-related research has demonstrated exciting therapeutic effects in glycemic control both in vivo and in vitro, and these results now have been translated into clinical practice. However, some critical potential problems have emerged from current clinical trials. Multi-center, large-scale, double-blind, and placebo-controlled studies with strict supervision are required before MSC transplantation can become a routine therapeutic approach for T2DM. We briefly review the molecular mechanism of MSC treatment for T2DM as well as the merits and drawbacks identified in current clinical trials.http://link.springer.com/article/10.1186/s13098-017-0233-1Mesenchymal stem cellsType 2 diabetes mellitusInsulin resistance |
| spellingShingle | Li Zang Haojie Hao Jiejie Liu Yijun Li Weidong Han Yiming Mu Mesenchymal stem cell therapy in type 2 diabetes mellitus Diabetology & Metabolic Syndrome Mesenchymal stem cells Type 2 diabetes mellitus Insulin resistance |
| title | Mesenchymal stem cell therapy in type 2 diabetes mellitus |
| title_full | Mesenchymal stem cell therapy in type 2 diabetes mellitus |
| title_fullStr | Mesenchymal stem cell therapy in type 2 diabetes mellitus |
| title_full_unstemmed | Mesenchymal stem cell therapy in type 2 diabetes mellitus |
| title_short | Mesenchymal stem cell therapy in type 2 diabetes mellitus |
| title_sort | mesenchymal stem cell therapy in type 2 diabetes mellitus |
| topic | Mesenchymal stem cells Type 2 diabetes mellitus Insulin resistance |
| url | http://link.springer.com/article/10.1186/s13098-017-0233-1 |
| work_keys_str_mv | AT lizang mesenchymalstemcelltherapyintype2diabetesmellitus AT haojiehao mesenchymalstemcelltherapyintype2diabetesmellitus AT jiejieliu mesenchymalstemcelltherapyintype2diabetesmellitus AT yijunli mesenchymalstemcelltherapyintype2diabetesmellitus AT weidonghan mesenchymalstemcelltherapyintype2diabetesmellitus AT yimingmu mesenchymalstemcelltherapyintype2diabetesmellitus |